To Hold or Not to Hold? Periprocedural Management of Glucagon-like Peptide-1 Receptor‑based Agonists (GLP‑1ra) in Patients with Diabetes and Obesity
Abstract
Glucagon-like peptide-1 receptor-based agonists have transformed the care of patients with diabetes and obesity. However, case reports that have associated their use with retained gastric contents and pulmonary aspiration have raised concerns regarding their safe use in patients undergoing procedures involving deep sedation, general anesthesia, or upper endoscopy. Here we present the evidence underlying these concerns and provide an evidence-informed framework for the periprocedural management of these agents. Further research is needed to better characterize these risks and provide mitigation strategies for individuals taking them in the perioperative period.
References
Kong F, Zhao Y, Zhang W, Wang X, Wu T, Zhou Z, et al. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Nature Commun. 2026;17:972. Published 2026 Jan 7. doi:10.1038/s41467-025-67701-9
Canadian Institute for Health Information (CIHI). Ozempic the leading medication driving growth in public drug spending in Canada [Internet]. March 10, 2026 [Accessed April 5, 2026]. Available from: https://www.cihi.ca/en/news/ozempic-the-leading-medication-driving-growth-in-public-drug-spending-in-canada
Jones KL, Huynh LQ, Hatzinikolas S, Rigda RS, Phillips LK, Pham HT, et al. Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations. Diabetes Obes Metab. 2020;22(5):788-797. doi:10.1111/dom.13956
Camilleri M, Carlson P, Dilmaghani S. Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide. Obesity (Silver Spring). 2024;32(2):232–233. doi:10.1002/oby.23941
Canada Institute for Safe Medication Practices (ISMP). Glucagon-like peptide-1 (GLP-1) receptor agonists: risk of aspiration during anesthesia. ISMP Canada Safety Bulletin. 2023;23(9):1-7.
Lamperti M, Romero CS, Guarracino F, Cammarota G, Vetrugno L, Tufegdzic B, et al. Preoperative assessment of adults undergoing elective noncardiac surgery: updated guidelines from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2025;42(1):1-35. doi:10.1097/EJA.0000000000002069
Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clin Gastroenterol Hepatol. 2025;23(12):2083-2085. doi:10.1016/j.cgh.2024.10.003
Hocking SL, Scott DA, Remedios ML, Horowitz M, Story DA, Greenfield JR, et al. 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists. Anaesth Intens Care. 2025;53(5):300-306. doi:10.1177/0310057X251355288
Oprea AD, Ostapenko LJ, Sweitzer B, Selzer A, Irizarry-Alvarado JM, Hurtado Andrade MD, et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth. 2025;135(1):48-78. doi:10.1016/j.bja.2025.04.001
El-Boghdadly K, Dhesi J, Fabb P, Levy N, Lobo DN, McKechnie A, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association. Anaesthesia. 2025;80(4):412-424. doi:10.1111/anae.16541
Goldenberg RM, Gilbert JD, Houlden RL, Khan TS, Makhija S, Mazer CD, et al. Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms. Curr Med Res Opin. 2025;41(3):403-419. doi:10.1080/03007995.2025.2458538
Jung HK, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Szarka LA, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225–1233. doi:10.1053/j.gastro.2008.12.047
Aljarallah BM. Management of diabetic gastroparesis. Saudi J Gastroenterol. 2011;17(2):97–104. doi:10.4103/1319-3767.77237
Izzy M, Lee M, Johns-Keating K, Kargoli F, Beckoff S, Chun K, et al. Glycosylated hemoglobin level may predict the severity of gastroparesis in diabetic patients. Diabetes Res Clin Pract. 2018;135:45–49. doi:10.1016/j.diabres.2017.10.016
Parkman HP, Natta MV, Yamada G, Grover M, McCallum RW, Sarosiek I, et al. Body weight in patients with idiopathic gastroparesis. Neurogastroenterol Motil. 2021;33(2):e13974. doi:10.1111/nmo.13974
Raven LM, Brown C, Greenfield JR. Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists. Med J Aust. 2024;220(1):14–16. doi:10.5694/mja2.52170
Chang S, Tang Y, Wang M, Zhu S, Tan X, Fan X, et al. Impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on increased residual gastric content in patients with and without concurrent colonoscopy: a retrospective case–control study. J Clin Med. 2026;15(6):2121. doi:10.3390/jcm15062121
Hiramoto B, McCarty TR, Lodhia NA, Jenkins A, Elnaiem A, Muftah M, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol. 2024;119(6):1126–1140. doi:10.14309/ajg.0000000000002820
Masselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171–192. doi:10.1007/5584_2020_496
Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886–1891. doi:10.1111/dom.14110
Meier JJ, Rosenstock J, Hincelin-Mery A, Roy-Duval C, Delfolie A, Coester HV, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263-1273. doi:10.2337/dc14-1984
Maselli D, Atieh J, Clark MM, Eckert D, Taylor A, Carlson P, et al. Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. Obesity (Silver Spring). 2022;30(8):1608-1620. doi:10.1002/oby.23481
Halawi H, Khemani D, Eckert D, O’Neill J, Kadouh H, Grothe K, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroeneterol Hepatol. 2017;2(12):890-899. doi:10.1016/S2468-1253(17)30285-6
Abu-Freha N, Levi Z, Nevo-Shor A, Guterman R, Elhayany R, Yitzhak A, et al. The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy. Diabetes Res Clin Pract. 2024;217:111900. doi:10.1016/j.diabres.2024.111900
Chapman MB, Norwood DA, Price C, Abdulhadi B, Kyanam Kabir Baig K, Ahmed AM, et al. Effects of glucagonlike peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD. Gastrointest Endosc. 2024;100(5):923–927. doi:10.1016/j.gie.2024.05.012
Phan J, Chang P, Issa D, Turner R, Dodge J, Westanmo A, et al. Glucagon-like peptide receptor agonists use before endoscopy is associated with low retained gastric contents: a multicenter cross-sectional analysis. Am J Gastroenterol. 2025;120(3):554-561. doi:10.14309/ajg.0000000000002969
Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091. doi:10.1016/j.jclinane.2023.111091
Stark JE, Cole JL, Ghazarian RN, Klass MJ. Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during Esophagogastroduodenoscopy (EGD). Ann Pharmacother. 2022;56(8):922–926. doi:10.1177/10600280211055804
Wu F, Smith MR, Mueller AL, Klapman SA, Everett LL, Houle T, et al. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study. Can J Anaesth. 2024;71(7):958–966. doi:10.1007/s12630-024-02719-z
Firkins SA, Yates J, Shukla N, Garg R, Vargo JJ, Lembo A, et al. Clinical outcomes and safety of upper endoscopy while on glucagon-like peptide-1 receptor agonists. Clin Gastroenterol Hepatol. 2025;23(5):872-873.e3. doi:10.1016/j.cgh.2024.03.013
Garza K, Aminpour E, Shah J, Mehta B, Early D, Gyawali CP, et al. Glucagon-like peptide-1 receptor agonists increase solid gastric residue rates on upper endoscopy especially in patients with complicated diabetes: a case-control study. Am J Gastroenterol. 2024;119(6):1081–1088. doi:10.14309/ajg.0000000000002777
Ghazanfar H, Javed N, Qasim A, Sosa F, Altaf F, Khan S, et al. Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study. World J Gastroenterol. 2024;30(26):3221–3228. doi:10.3748/wjg.v30.i26.3221
Robalino Gonzaga E, Farooq A, Mohammed A, Chandan S, Fawwaz B, Singh G, et al. Real-world impact of GLP-1 receptor agonists on endoscopic patient outcomes in an ambulatory setting: a retrospective study at a large tertiary center. J Clin Med. 2024;13(18):5403. doi:10.3390/jcm13185403
Kobori T, Onishi Y, Yoshida Y, Tahara T, Kikuchi T, Kubota T, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy. J Diabetes Investig. 2023;14(6):767–773. doi:10.1111/jdi.14005
Maselli DB, Lee D, Bi D, Jirapinyo P, Thompson CC, Donnangelo LL, et al. Safe continuation of glucagon-like peptide 1 receptor agonists at endoscopy: a case series of 57 adults undergoing endoscopic sleeve gastroplasty. Obes Surg. 2024;34(7):2369–2374. doi:10.1007/s11695-024-07278-2
Nadeem D, Taye M, Still MD, McShea S, Satterfield D, Dove JT, et al. Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients. Gastrointest Endosc. 2024;100(4):745–749. doi:10.1016/j.gie.2024.04.2900
Nasser J, Hosseini A, Barlow G, Gianchandani R, Rezaie A, Pimentel M, et al. Food retention at endoscopy among adults using glucagon-like peptide-1 receptor agonists. JAMA Netw Open. 2024;7(10):e2436783. doi:10.1001/jamanetworkopen.2024.36783
Maselli DB, Lee, D, Bi D, Jirapinyo P, Thompson CC, Donnangelo LL, et al. Safe continuation of glucagon-like peptide 1 receptor agonists at endoscopy: a case series of 57 adults undergoing endoscopic sleeve gastroplasty. Obes Surg. 2024;34:2369-2374. doi:10.1007/s11695-024-07278-2
Baldawi M, Ghaleb N, McKelvey G et al. Preoperative ultrasound assessment of gastric content in patients with diabetes: a meta-analysis based on a systematic review of the current literature. J Clin Anesth. 2024;93:111365. doi:10.1016/j.jclinane.2023.111365
Facciorusso A, Ramai D, Dhar J, Samanta J, Chandan S, Gkolfakis P, et al. Effects of Glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis. Clin Gasteroenterol Hepatol. 2025;23(5):715-725.e3. doi:10.1016/j.cgh.2024.07.021
Fujino E, Cobb KW, Schoenherr J, Gouker L, Lund E. Anesthesia considerations for a patient on semaglutide and delayed gastric emptying. Cureus. 2023;15(7):e42153. doi:10.7759/cureus.42153
Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023;70(8):1394–1396. doi:10.1007/s12630-023-02440-3
Raven LM, Stoita A, Feller RB, Brown C, Greenfield JR. Delayed gastric emptying with perioperative use of glucagon-like peptide-1 receptor agonists. Am J Med. 2023;136(12):e233–e234. doi:10.1016/j.amjmed.2023.07.016
Nersessian RSF, da Silva LM, Carvalho MAS, Silveira SQ, Abib ACV, Bellicieri FN, et al. Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study. Anaesthesia. 2024;79(12):1317–1324. doi:10.1111/anae.16454
Potnuru PP, Hernandez N, Nwokolo OO, Sen S. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. Comment on Br J Anaesth. 2024;132:644-648. Br J Anaesth. 2024;133(4):884–886. doi:10.1016/j.bja.2024.05.043
Avraham SA, Hossein J, Somri F, Hawash N, Hochman O. Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss. Anaesth Rep. 2024;12(1):e12278. doi:10.1002/anr3.12278
Gulak MA, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. Régurgitation sous anesthésie chez une personne à jeun à qui du sémaglutide a été prescrit pour une perte de poids : une présentation de cas. Can J Anaesth. 2023;70(8):1397-1400. doi:10.1007/s12630-023-02521-3
Weber M, Siddarthan I, Mack PF. Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss. Br J Anaesth. 2023;131(2):e37–e39. doi:10.1016/j.bja.2023.05.005
Fanizza BS, Moghaddam AS, Atrash A. Are patient factors associated with adverse perioperative outcomes in GLP-1 receptor agonist users? A retrospective cohort study. J Clin Anesth. Published online March 26, 2026. doi:10.1016/j.jclinane.2026.112192
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Canadian Diabetes & Endocrinology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
